Extrahepatic cancers and chronic HCV infection

Area of Science:

• Hepatology
• Oncology
• Virology

Background:

• Hepatitis C virus (HCV) is implicated in approximately 15% of human cancers.
• Chronic HCV infection can lead to persistent inflammation and immune dysregulation, contributing to neoplasia.
• HCV affects both liver and extrahepatic cells, increasing cancer risk.

Purpose of the Study:

• To review recent studies on the risk of extrahepatic cancers associated with chronic HCV infection.
• To clarify the causal relationship between HCV and various cancers, especially non-Hodgkin lymphoma (NHL).
• To evaluate the impact of sustained virologic response (SVR) on cancer risk and prognosis.

Main Methods:

• Review of epidemiological studies and meta-analyses.
• Analysis of data on HCV infection rates in cancer patients.
• Examination of mechanisms involved in HCV-related lymphomagenesis.
• Assessment of the impact of antiviral therapy and SVR on cancer outcomes.

Main Results:

• A clear causal link exists between HCV and NHL, with a relative risk of approximately 1.5.
• HCV infection is associated with an increased risk of intrahepatic cholangiocarcinoma.
• SVR achieved through antiviral treatment can improve lymphoma prognosis and may induce remission in indolent forms.
• The causal relationship between HCV and other extrahepatic cancers requires further prospective evidence.

Conclusions:

• HCV is a direct and indirect cause of NHL and cholangiocarcinoma.
• Antiviral therapy leading to SVR is crucial for improving outcomes in HCV-related cancers.
• Further research is needed to confirm the link between HCV and other extrahepatic malignancies and the benefit of SVR for these conditions.